(R)-6-(benzyloxy)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromane | 906079-31-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (R)-6-(benzyloxy)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromane
• 英文别名: (2R)-2,5,7,8-tetramethyl-6-phenylmethoxy-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromene
• CAS: 906079-31-0
• 化学式: C₃₆H₅₀O₂
• 分子量: 514.792
• InChiKey: DYWHBKHFBOGTDM-QUCWQQGTSA-N

物化性质

• 沸点：
  607.4±54.0 °C(Predicted)
• 密度：
  0.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  10.47
• 重原子数：
  38.0
• 可旋转键数：
  12.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  (R)-6-(benzyloxy)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromane 在 lithium 、 乙胺 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以83%的产率得到α-生育三烯醇
  参考文献：
  名称：

  Chemoenzymatic synthesis of both enantiomers of α-tocotrienol

  摘要：

  The stereoselective acylation of the achiral chromanedimethanol derivative 1 by vinyl acetate in the presence of Candida antarctica lipase B gave the (S)-monoester 2 in high enantiomeric purity (ee >= 98%). Enzymatic hydrolysis of diesters of compound I failed to give (R)-monoester 2 in good yield and high ee. Thus, both enantiomers of alpha-tocotrienol were synthesized from the (S)-monoester 2. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.035
• 作为产物：
  描述：

  [(2S)-6-hydroxy-2-(hydroxymethyl)-5,7,8-trimethyl-3,4-dihydrochromen-2-yl]methyl acetate 在 [1,3-双(二苯基膦基)丙烷]二氯化钯(II) 咪唑 、 六甲基磷酰三胺 、 4-二甲氨基吡啶 、 正丁基锂 、 乙基溴化镁 、 四丁基氟化铵 、 sodium hydride 、 三乙基硼氢化锂 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 440.5h， 生成 (R)-6-(benzyloxy)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromane
  参考文献：
  名称：

  Chemoenzymatic synthesis of both enantiomers of α-tocotrienol

  摘要：

  The stereoselective acylation of the achiral chromanedimethanol derivative 1 by vinyl acetate in the presence of Candida antarctica lipase B gave the (S)-monoester 2 in high enantiomeric purity (ee >= 98%). Enzymatic hydrolysis of diesters of compound I failed to give (R)-monoester 2 in good yield and high ee. Thus, both enantiomers of alpha-tocotrienol were synthesized from the (S)-monoester 2. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.035

文献信息

• WO2021067836A5
  申请人：——

  公开号：WO2021067836A5

  公开（公告）日：2024-03-28
• CHINONE-, HYDROCHINOME- AND NAPHTHOCHINONE-ANALOGUES OF VATIQUIONE FOR TREATMENT OF MITOCHONDRIAL DISORDER DISEASES
  申请人：Stealth BioTherapeutics Inc.

  公开号：EP4038076A1

  公开（公告）日：2022-08-10
• COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA
  申请人：Keefe Dennis

  公开号：US20210206736A1

  公开（公告）日：2021-07-08

  The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).
• [EN] CHINONE-, HYDROCHINOME- AND NAPHTHOCHINONE-ANALOGUES OF VATIQUIONE FOR TREATMENT OF MITOCHONDRIAL DISORDER DISEASES<br/>[FR] ANALOGUES CHINONE, HYDROCHINONE ET NAPHTOCHINONE DE VATIQUINONE POUR LE TRAITEMENT DE MALADIES À TROUBLES MITOCHONDRIAUX
  申请人：STEALTH BIOTHERAPEUTICS CORP

  公开号：WO2021067836A1

  公开（公告）日：2021-04-08

  The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g. Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).